A study of 39,184 people with solid tumors, published Oct. 8, 2026, found that about 1 in 6 had an inherited genetic change that increased their cancer risk. Testing only people under 50 would have missed 72% of those with these changes.
In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.